Pfizer ADC Adcetris gains additional lymphoma indication

Massimo Giachetti
- The U.S. FDA has granted an additional approval for Pfizer’s (NYSE:PFE) antibody-drug conjugate Adcetris (brentuximab vedotin), this time for large B-cell lymphoma (LBCL).
- The new indication is specifically as a third-line therapy for those ineligible for autologous hematopoietic stem cell